Original Article
Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma Hui Yu1, Xiuying Huang1, Zhihua Zhu1, Yi Hu1, Wei Ou1, Lanjun Zhang1, Ningning Zhou2 1
Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative
Innovation Center for Cancer Medicine, Guangzhou 510060, P.R. China; 2Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P.R. China. Corresponding to: Zhihua Zhu, MD, PhD, Associate professor, Master tutor. State Key Laboratory of Oncology in South China, Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China. Email: [email protected]; [email protected]. Objective: To evaluate the significance of combined detection of LunX mRNA, carcinoembryonic antigen
(CEA), neuron-specific enolase (NSE), and cytokeratin 21-1 fragment (CYFRA21-1) in clinical diagnosis of lung carcinoma. Methods: Based on the quantitative RT-PCR and chemiluminescence immunoassay, the expression levels
of LunX mRNA, CEA, NSE, and CYFRA21-1 in 113 patients with lung carcinoma (case group) and 30 healthy participants (control group) were detected. Meantime, the sensitivity, specificity, and accuracy of the combination detection were also explored. Results: The positive rates of LunX mRNA in peripheral blood and CEA, NSE, and CYFRA21-1 in serum were significantly higher in case group than those in control group (χ2=17.295, 16.825, 19.148, and 17.450;
P0.05). The positive rate of LunX mRNA in stage I + II, III, and IV had a significantly increasing tendency (χ2=10.565, 32.462, P15.2 ng/mL, CYFRA21-1 >3.3 ng/mL, and CEA >5 ng/mL. Statistical analysis Statistical analyses were implemented by using SPSS 13.0 statistical software. Sample frequency was analyzed by commonly used χ 2 test. Categorical variables were compared by Kruskal-wallis Test, with the test level α=0.05. The sensitivity, specificity and accuracy were estimated according to the following formula described in literature (1). Sensitivity =A/(A+C)×100%; specificity =D/ (B+D)×100%; accuracy = A+D/(A+B+C+D)×100% (A, number of true positive samples; B, number of false positive samples; C, number of false negative samples; D, number of true negative samples. Results Inter-group comparison of positive rates in peripheral blood levels of LunX mRNA, CEA, NSE and CYFRA21-1 Positive results was defined as peripheral blood level
© Chinese Journal of Cancer Research. All rights reserved.
of LunX mRNA >10 3 copies/mL. The positive rates of peripheral blood levels of LunX mRNA, CEA, NSE and CYFRA21-1 were statistically higher in NSCLC patients compared with those in controls (χ2=17.295, 16.825, 19.148, and 17.450, respectively, P0.05). The highest CEA-positive rate was observed in the peripheral blood of patients with lung adenocarcinoma (χ2=33.154, P
Significance of combined detection of LunX mRNA and tumor markers in diagnosis of lung carcinoma Hui Yu1, Xiuying Huang1, Zhihua Zhu1, Yi Hu1, Wei Ou1, Lanjun Zhang1, Ningning Zhou2 1
Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative
Innovation Center for Cancer Medicine, Guangzhou 510060, P.R. China; 2Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P.R. China. Corresponding to: Zhihua Zhu, MD, PhD, Associate professor, Master tutor. State Key Laboratory of Oncology in South China, Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China. Email: [email protected]; [email protected]. Objective: To evaluate the significance of combined detection of LunX mRNA, carcinoembryonic antigen
(CEA), neuron-specific enolase (NSE), and cytokeratin 21-1 fragment (CYFRA21-1) in clinical diagnosis of lung carcinoma. Methods: Based on the quantitative RT-PCR and chemiluminescence immunoassay, the expression levels
of LunX mRNA, CEA, NSE, and CYFRA21-1 in 113 patients with lung carcinoma (case group) and 30 healthy participants (control group) were detected. Meantime, the sensitivity, specificity, and accuracy of the combination detection were also explored. Results: The positive rates of LunX mRNA in peripheral blood and CEA, NSE, and CYFRA21-1 in serum were significantly higher in case group than those in control group (χ2=17.295, 16.825, 19.148, and 17.450;
P0.05). The positive rate of LunX mRNA in stage I + II, III, and IV had a significantly increasing tendency (χ2=10.565, 32.462, P15.2 ng/mL, CYFRA21-1 >3.3 ng/mL, and CEA >5 ng/mL. Statistical analysis Statistical analyses were implemented by using SPSS 13.0 statistical software. Sample frequency was analyzed by commonly used χ 2 test. Categorical variables were compared by Kruskal-wallis Test, with the test level α=0.05. The sensitivity, specificity and accuracy were estimated according to the following formula described in literature (1). Sensitivity =A/(A+C)×100%; specificity =D/ (B+D)×100%; accuracy = A+D/(A+B+C+D)×100% (A, number of true positive samples; B, number of false positive samples; C, number of false negative samples; D, number of true negative samples. Results Inter-group comparison of positive rates in peripheral blood levels of LunX mRNA, CEA, NSE and CYFRA21-1 Positive results was defined as peripheral blood level
© Chinese Journal of Cancer Research. All rights reserved.
of LunX mRNA >10 3 copies/mL. The positive rates of peripheral blood levels of LunX mRNA, CEA, NSE and CYFRA21-1 were statistically higher in NSCLC patients compared with those in controls (χ2=17.295, 16.825, 19.148, and 17.450, respectively, P0.05). The highest CEA-positive rate was observed in the peripheral blood of patients with lung adenocarcinoma (χ2=33.154, P
